New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
11:36 EDTPFE, BMYPfizer CFO says partnership on Eliquis with Bristol-Myers 'going well'
News For PFE;BMY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 22, 2015
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
08:49 EDTBMYBristol-Myers price target raised to $70 from $63 at SunTrust
Subscribe for More Information
January 21, 2015
12:30 EDTPFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:16 EDTBMYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 20, 2015
16:34 EDTBMYBristol-Myers appoints Giovanni Caforio CEO
Bristol-Myers Squibb announced a number of leadership changes approved by its board of directors and effective at the close of the annual Shareholders’ Meeting on May. Giovanni Caforio, M.D. will become CEO of the company. Lamberto Andreotti will become executive chairman of the board of directors on May 5 and will continue to serve as chairman after his retirement on August 3. James M. Cornelius, 71, has chosen not to stand for re-election as non-executive chairman and will retire from the board. Togo D. West, Jr., 72, will become the lead independent director on the company’s board.
January 15, 2015
11:20 EDTPFEGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
07:59 EDTPFEAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
January 13, 2015
14:15 EDTBMYBristol-Myers treatment of acute myeloid leukemia gets FDA orphan designation
According to a post on the FDA's website, Bristol-Myers' treatment of acute myeloid leukemia, ulocuplumab, received orphan designation. Reference Link
12:27 EDTBMYDOJ, EPA report proposed settlement regarding cleanup of Warren County, NJ site
Subscribe for More Information
08:09 EDTBMYBristol-Myers price target raised to $72 from $66 at Leerink
Leerink raised its price target for Bristol-Myers to $72 saying the earlier stop of the Opdivo trial affirms the drug's potential survival benefits across multiple cancers. Leerink says it now has increased confidence in positive readouts for Bristol's upcoming survival studies in non-squamous non-small cell lung cancer and kidney cancer. The firm reiterates an Outperform rating on the stock.
08:05 EDTBMYBristol-Myers Eli Lilly enter clinical collaboration pact for Opdivo combo
Subscribe for More Information
07:42 EDTBMYJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
January 12, 2015
12:45 EDTPFEActavis CEO says 'can't speculate on what Pfizer is going to do'
Subscribe for More Information
09:22 EDTPFE23andMe announces collaboration with Pfizer
Google (GOOG)-backed 23andMe announced an agreement with Pfizer (PFE) that will provide Pfizer with access to 23andMe’s research platform, including services and Research Portal analysis of 23andMe’s genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe’s Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company’s unique research model while still protecting the privacy and security of 23andMe’s customers. As a part of the agreement, the companies will collaborate on certain genome-wide association studies, surveys, and clinical trial recruitment. One of these collaborations will be a longitudinal study to better understand the genetics of lupus. This study will entail enrollment and genotyping of 5,000 people into a new lupus research community, and include the integration of medical records, targeted bio-sampling along with genetic information for all participants. This announcement follows a collaboration between 23andMe and Pfizer to enroll 10,000 people with Inflammatory Bowel Disease in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Nearly 4,000 patients have been enrolled in the community since August 2014.
09:00 EDTBMYBristol-Myers price target raised to $70 from $62 at Argus
Subscribe for More Information
08:37 EDTPFE, BMYShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:15 EDTBMYSeattle Genetics announces clinical trial collaboration with Bristol-Myers
Subscribe for More Information
08:06 EDTBMYBristol-Myers shares expected to trade up around 10% at JPMorgan
JPMorgan expects shares of Bristol-Myers to trade up around 10% after the company announced that its Phase III trial of Opdivo in 2L squamous non-small cell lung cancer is stopping early due to efficacy. The firm views the news as a "clear positive" that sets up a potential 2015 filing and launch for the product in the 2L squamous market. It reiterates an Overweight rating on shares of the Bristol-Myers. The stock is up 7% to $64.25 in pre-market trading.
05:26 EDTBMYBristol-Myers up 5.6% after Opdivo Phase 3 study meets primary endpoint
Subscribe for More Information
05:06 EDTBMYBristol-Myers Opdivo Phase 3 study met primary endpoint
Bristol-Myers Squibb announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer, or NSCLC, was stopped early because an assessment conducted by the independent Data Monitoring Committee, or DMC, concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company will share these data – which for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer – with health authorities. CheckMate -017 investigators are being informed of the decision to stop the comparative portion of the trial. Bristol-Myers Squibb is working to ensure that eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension as part of the company’s commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -017 data and work with investigators on the future presentation and publication of the results.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use